Embedded Files
Protara Therapeutics shares fell >26% after interim Phase II ADVANCED-2 data in BCG-unresponsive non-muscle-invasive Bladder Cancer showed complete responses of 68.2% at 6 months (n=22) but 33.3% at 12 months (n=15), with durability still maturing. In the BCG-naïve cohort, CR was 66.7% at 6 months (n=27) and 57.9% at 12 months (n=19), with no grade ≥3 treatment-related AEs reported.
Why It Matters To Oncology
TARA-002 is a TLR2/NOD2 agonist immunopotentiator (inactivated Streptococcus pyogenes) designed to activate innate and adaptive immunity, potentially offering a differentiated intravesical immunotherapy approach in NMIBC.
The key clinical question is durability: the BCG-unresponsive cohort’s CR rate declined from 6 to 12 months, though Protara highlighted that all five patients assessed from 9–12 months maintained CR.
Re-induction may matter operationally and clinically: 61.5% of re-induced patients converted to CR at 6 months, suggesting a potential strategy to recapture responses.
Tolerability looked favorable for an intravesical regimen: most TRAEs were mild/transient, with no grade ≥3 TRAEs or discontinuations; common events included dysuria, bladder spasm, fatigue, and urgency.
The Financials
Shares slid more than 26% Tuesday as investors appeared to focus on still-immature 12-month durability data despite early response signals.
The market reaction underscores how NMIBC programs can trade on durability curves and evaluable-patient attrition at later timepoints (e.g., 12-month n=15 in BCG-unresponsive).
What They're Saying
Oppenheimer: The readout suggests TARA-002 has “solid prospects to compete in this evolving therapeutic marketplace,” citing practical and tolerability advantages, and called the 9–12 month durability in evaluable patients a “robust indication of CR durability.”
CEO Jesse Shefferman: TARA-002 “demonstrat[es] impressive efficacy and safety” and could overcome limitations of existing NMIBC treatments that burden patients and urology practices.
What's Next
ADVANCED-2 data are slated for presentation Friday at ASCO-GU.
Protara expects to complete enrollment of the BCG-unresponsive cohort in the second half.
A registrational study (ADVANCED-3) in BCG-naïve patients is planned to start in the second half.
Page updated
Report abuse